Stamcellen uit patient zelf en op bepaalde manier gelabeld, bewerkt zorgt voor opmerkelijk resultaten in dierproeven bij elimineren van uitzaaiingen. 38% herstelde tegenover 0% in placebogroep.

1 juni 2010: Bron: Cancer Research 69, 4134, May 15, 2009. Published Online First May 12, 2009; doi: 10.1158/0008-5472.CAN-08-4698

Stamcellen uit beenmerg van patient en op een bepaalde manier bewerkt (gelabeld met een virus bv.) zorgt voor opmerkeljike resultaten bij het stoppen en elimineren van uitgezaaide kanker bij dierproeven. Bij de groep van muizen waarbij de stamcellen werden gebruikt bleek 38% de uitgezaaide tumoren kwijt te raken tegenover 0% in de placebogroep. Hier het abstract van de studie waarvan u het volledige studieverslag als u hier klikt kunt lezen. Het is mij te ingewikkeld om dit nader te verklaren. Maar artsen en wetenschappers zullen ongetwijfeld weten hoe dit in zijn werk gaat. Twee geraadpleegde artsen vonden dit zeer interessant.

Mesenchymal Stem Cell delivery of TRAIL can eliminate Metastatic Cancer

Michael R. Loebinger,¹ Ayad Eddaoudi,² Derek Davies,³ and Sam M. Janes¹^*

¹Centre For Respiratory Research, Rayne Institute, University College London, 5 University Street, London, WC1E 6JJ, England

²Flow Cytometry Facility, Institute of Child Health, University College London, 30 Guildford Street, London, WC1N 1EH, England

³Flow Cytometry Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London, WC2A 3PX, England

^*Corresponding author Telephone: +44 20 7679 6926, Fax: +44 20 7679 6973 e-mail: s.janes@ucl.ac.uk

Cancer is a leading cause of mortality throughout the world and new treatments are urgently needed. Recent studies suggest that bone marrow-derived mesenchymal stem cells (MSCs) home to and incorporate within tumor tissue. We hypothesised that MSCs engineered to produce and deliver TNF-related apoptosis-inducing ligand (TRAIL), a transmembrane protein which causes selective apoptosis of tumor cells, would home to and kill cancer cells in a lung metastatic cancer model.

Human MSCs were transduced with TRAIL and the IRES-eGFP reporter gene, under the control of a tetracycline promoter using a lentiviral vector. Transduced and activated MSCs caused lung (A549), breast (MDAMB231), squamous (H357), and cervical (Hela) cancer cell apoptosis and death in co-culture experiments. Subcutaneous xenograft experiments confirmed directly delivered TRAIL-expressing MSCs were able to significantly reduce tumor growth (0.12 cm³ (0.04-0.21) vs 0.66 cm³ (0.21-1.11) (p<0.001)). We then found using a pulmonary metatastasis model, systemically delivered MSCs localised to lung metastases and the controlled local delivery of TRAIL completely cleared the metastatic disease in 38% of mice compared to 0% of controls (p<0.05).

This is the first study to demonstrate a significant reduction in metastatic tumor burden with frequent eradication of metastases using inducible TRAIL-expressing MSCs. This has a wide potential therapeutic role, which includes the treatment of both primary tumors and their metastases, possibly as an adjuvant therapy in clearing micrometastatic disease following primary tumor resection.

metastases, uitzaaiingen, stamcellen